The Discounted Cash Flow (DCF) valuation of Apellis Pharmaceuticals Inc (APLS) is (106.56) USD. With the latest stock price at 23.13 USD, the upside of Apellis Pharmaceuticals Inc based on DCF is -560.7%.
Based on the latest price of 23.13 USD and our DCF valuation, Apellis Pharmaceuticals Inc (APLS) is a sell. selling Apellis stocks now will result in a potential gain of 560.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.0% - 8.2% | 7.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (309.13) - (65.93) | (106.56) |
| Upside | -1436.5% - -385.1% | -560.7% |